Abstract
Background We performed the first autologous oral mucosa-derived epithelial cell sheet transplantation therapy in a patient with refractory postoperative anastomotic stricture in congenital esophageal atresia (CEA) and confirmed its safety. In this study, patients with CEA and congenital esophageal stenosis (CES) were newly added as subjects to further evaluate the safety and efficacy of cell sheet transplantation therapy.
Methods Epithelial cell sheets were prepared from the oral mucosa of the subjects and transplanted into esophageal tears created by endoscopic balloon dilatation (EBD). The safety of the cell sheets was confirmed by quality control testing, and the safety of the transplantation treatment was confirmed by 48-week follow-up examinations.
Results Subject 1 had a stenosis resected because the frequency of EBD did not decrease after the second transplantation. Histopathological examination of the resected stenosis revealed marked thickening of the submucosal layer. Subject 2 did not require EBD for more than 18 months after transplantation, and Subject 3 did not require EBD for at least 9 months after transplantation, during which time they were able to maintain a normal diet by mouth.
Conclusions Subject 2 was free of EBD for a long period of time after transplantation, confirming that cell sheet transplantation therapy is clearly effective in some cases. In the future, it is necessary to study more cases; develop new technologies such as an objective index to evaluate the efficacy of cell sheet transplantation therapy and a device to achieve more accurate transplantation; identify cases in which the current therapy is effective; find the optimal timing of transplantation; and clarify the mechanism by which the current therapy improves stenosis.
Trial registration UMIN, UMIN000034566, registered 19 October 2018, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039393.
Competing Interest Statement
AU is a co-researcher with CellSeed Inc. MM is the CEO of MakeWay LLC. The other authors have no conflicts of interest regarding the work described herein.
Clinical Trial
UMIN000034566
Funding Statement
This research was supported by AMED (JP18bk0104006, JP22bk0104140).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The entire study including the clinical intervention component and experiments with human cells and tissues was approved by the Institutional Review Board and Certified Special Committee for Regenerative Medicine at the National Center for Child Health and Development. Human cells in this study were utilized in full compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Ministry of Health, Labor, and Welfare (MHLW), Japan; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan). Informed consent to participate in this study was obtained from the parents of the patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 1 was revised.
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
List of abbreviations
- CEA
- congenital esophageal atresia
- CES
- congenital esophageal stenosis
- EBD
- Endoscopic balloon dilatation
- ESD
- Endoscopic submucosal dissection
- ESCC
- Esophageal squamous cell carcinoma
- CPF
- Cell processing facility
- SOP
- Standard operating procedures
- EDTA
- Ethylenediamine tetraacetic acid tetrasodium
- KCM
- Keratinocyte culture medium
